Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Multi-Center Retrospective Evaluation of High-Dose Cytarabine Based Induction Versus CPX-351 Induction in Patients with Secondary AML

Lydia Benitez, PharmD, Anthony J. Perissinotti, PharmD, Caitlin R. Rausch, PharmD, Jeff Klaus, PharmD, Stephen Michael Clark, PharmD, Michael Filtz, PharmD, Kelley L Ratermann, PharmD, Carissa F. Treptow, PharmD, Shawn Griffin, PharmD, Marissa Olson, PharmD, Mallory Crain, PharmD, Kristen Pettit, MD, Patrick W. Burke, MD, Dale L. Bixby, MD, Bernard Lawrence Marini, PharmD

Blood (2019) 134 (Supplement_1): 2639.

https://doi.org/10.1182/blood-2019-122189

Published: 2019

Journal Articles

Ruxolitinib in Combination with Dasatinib and Dexamethasone Is an Active and Well-Tolerated Chemotherapy-Sparing Oral Induction Regimen for Adults with Philadelphia Chromosome-Positive ALL: Results of a Phase I Trial

Mark Blaine Geyer, MD, Patrick W. Burke, MD, Amber C. King, PharmD, BCOP, Michael J. Mauro, MD, Martin S. Tallman, MD, Ross L. Levine, MD, Charles J. Sherr, MD PhD, Dan Douer, MD, Jae H. Park, MD

Blood (2018) 132 (Supplement 1): 2692.

https://doi.org/10.1182/blood-2018-99-110537

Published: 2018

Journal Articles

Lenalidomide Plus Hypomethylating Agent for Acute Myeloid Leukemia (AML) with Recurrent Genetic Abnormalities -AML with Inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, Mecom

Lauren E. Merz, BA, Anthony J. Perissinotti, PharmD, Bernard Lawrence Marini, PharmD, Ashley Crouch, BS, Kristen Pettit, MD, Patrick W. Burke, MD, Harry P. Erba, MD PhD, Dale L. Bixby, MD PhD

Blood (2018) 132 (Supplement 1): 4042.

https://doi.org/10.1182/blood-2018-99-110854

Published: 2018

Journal Articles

a Phase 1b/2 Study of TAK-659, an Investigational Dual SYK and FLT-3 Inhibitor, in Patients (Pts) with Relapsed or Refractory Acute Myelogenous Leukemia (R/R AML)

Jason B Kaplan, MD, Dale L. Bixby, MD, John C Morris, MD, Olga Frankfurt, MD, Jessica Altman, Trisha Wise-Draper, MD PhD, Patrick W. Burke, MD, Sabrina Collins, BS, Karuppiah Kannan, PhD, Ling Wang, PhD, Stephanie Faucette, PharmD, PhD, Benjamin Lee, MD PhD, Yaping Shou, MD PhD, Mark J. Levis, MD PhD, Keith W. Pratz, MD

Blood (2016) 128 (22): 2834.

https://doi.org/10.1182/blood.V128.22.2834.2834

Published: 2016

Journal Articles

Frequency and Characteristics of Pegaspargase Antibodies in Adults Treated with a Pediatric Acute Lymphoblastic Leukemia Regimen

Patrick W. Burke, MD, Ibrahim Aldoss, MD, Laleh Ramezani, BSc, Vinod Pullarkat, MD, Ann Mohrbacher, MD, Dan Douer, MD

Blood (2014) 124 (21): 936.

https://doi.org/10.1182/blood.V124.21.936.936

Published: 2014

Journal Articles

High-Grade Pegylated Asparaginase-Related Hepatotoxicity Occurrence In a Pediatric-Inspired Adult Acute Lymphoblastic Leukemia Regimen Does Not Necessarily Predict Recurrent Hepatotoxicity In Subsequent Cycles

Patrick W. Burke, MD, Ibrahim Aldoss, MD, Matthew A. Lunning, DO, Vassilios I. Avramis, PhD, Ann M. Mohrbacher, MD, Vinod Pullarkat, MD, Martin S. Tallman, MD, Dan Douer, MD

Blood (2013) 122 (21): 2671.

https://doi.org/10.1182/blood.V122.21.2671.2671

Published: 2013

NARROW

Multi-Center Retrospective Evaluation of High-Dose Cytarabine Based Induction Versus CPX-351 Induction in Patients with Secondary AML

Ruxolitinib in Combination with Dasatinib and Dexamethasone Is an Active and Well-Tolerated Chemotherapy-Sparing Oral Induction Regimen for Adults with Philadelphia Chromosome-Positive ALL: Results of a Phase I Trial

Lenalidomide Plus Hypomethylating Agent for Acute Myeloid Leukemia (AML) with Recurrent Genetic Abnormalities -AML with Inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, Mecom

a Phase 1b/2 Study of TAK-659, an Investigational Dual SYK and FLT-3 Inhibitor, in Patients (Pts) with Relapsed or Refractory Acute Myelogenous Leukemia (R/R AML)

Frequency and Characteristics of Pegaspargase Antibodies in Adults Treated with a Pediatric Acute Lymphoblastic Leukemia Regimen

High-Grade Pegylated Asparaginase-Related Hepatotoxicity Occurrence In a Pediatric-Inspired Adult Acute Lymphoblastic Leukemia Regimen Does Not Necessarily Predict Recurrent Hepatotoxicity In Subsequent Cycles

Email alerts

ASH Publications

American Society of Hematology

Multi-Center Retrospective Evaluation of High-Dose Cytarabine Based Induction Versus CPX-351 Induction in Patients with Secondary AML

Ruxolitinib in Combination with Dasatinib and Dexamethasone Is an Active and Well-Tolerated Chemotherapy-Sparing Oral Induction Regimen for Adults with Philadelphia Chromosome-Positive ALL: Results of a Phase I Trial

Lenalidomide Plus Hypomethylating Agent for Acute Myeloid Leukemia (AML) with Recurrent Genetic Abnormalities -AML with Inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, Mecom

a Phase 1b/2 Study of TAK-659, an Investigational Dual SYK and FLT-3 Inhibitor, in Patients (Pts) with Relapsed or Refractory Acute Myelogenous Leukemia (R/R AML)

Frequency and Characteristics of Pegaspargase Antibodies in Adults Treated with a Pediatric Acute Lymphoblastic Leukemia Regimen

High-Grade Pegylated Asparaginase-Related Hepatotoxicity Occurrence In a Pediatric-Inspired Adult Acute Lymphoblastic Leukemia Regimen Does Not Necessarily Predict Recurrent Hepatotoxicity In Subsequent Cycles

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only